Systems and methods for submucosal tissue separation

US11793539B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11793539-B2
Application numberUS-202016952849-A
CountryUS
Kind codeB2
Filing dateNov 19, 2020
Priority dateMay 19, 2017
Publication dateOct 24, 2023
Grant dateOct 24, 2023

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present disclosure relates to the field of medical devices generally and specifically, to endoscopic systems and methods for resection of malignant and pre-malignant lesions within the gastrointestinal (GI) tract. In particular, the present disclosure relates to systems and methods for delivering injectable compositions between tissue layers (e.g., between the muscularis and submucosa layers) to elevate and stabilize the lesion for fast and efficient resection.

First claim

Opening claim text (preview).

What is claimed is: 1. A system, comprising: a delivery device comprising a proximal portion, distal portion and lumen extending therebetween; a first injectable composition disposed within the distal portion of the delivery device; and a second injectable composition disposed within the proximal portion of the delivery device; wherein a viscosity of the first injectable composition is less than a viscosity of the second injectable composition; wherein the first and second injectable compositions are separated by a barrier member; and wherein the system is configured to sequentially deliver the first and second injectable compositions. 2. The system of claim 1 , wherein the barrier member is configured to rupture above a threshold level of force. 3. The system of claim 1 , wherein the barrier member includes a biocompatible or biodegradable material. 4. The system of claim 1 , wherein the second injectable composition comprises a hydrophilic polymer selected from the group consisting of acrylate-based polymers, polyurethane-based polymers, polynorbornene-based polymer and polylactide-based polymers. 5. The system of claim 4 , wherein the hydrophilic polymer further comprises a polysaccharide. 6. The system of claim 5 , wherein the polysaccharide is a xanthan gum. 7. The system of claim 1 , wherein the delivery device includes a sharpened distal end. 8. The system of claim 1 , wherein the delivery device is configured to be delivered through a working channel of an endoscope. 9. A system, comprising: a delivery device comprising a proximal portion, distal portion and lumen extending therebetween; a first injectable composition disposed within the distal portion of the delivery device; and a second injectable composition disposed within the proximal portion of the delivery device; wherein a viscosity of the first injectable composition is less than a viscosity of the second injectable composition; wherein the first and second injectable compositions are separated by a barrier member; wherein the delivery device is configured to (a) extend through a working channel of an endoscope that comprises a proximal end, a distal end and said working channel such that a distal end of the delivery device extends into tissue beyond the distal end of the endoscope and such that the distal end of the delivery device is positioned between adjacent first and second tissue layers and (b) inject the first and second injectable compositions between the first and second layers; and wherein the system is configured to sequentially deliver the first and second injectable compositions. 10. The system of claim 9 , wherein the barrier member is configured to rupture above a threshold level of force. 11. The system of claim 9 , wherein the barrier member includes a biocompatible or biodegradable material. 12. The system of claim 9 , wherein the viscosity of the second injectable composition is at least ten times greater than the viscosity of the first injectable composition. 13. The system of claim 9 , wherein the second injectable composition comprises a hydrophilic polymer selected from the group consisting of acrylate-based polymers, polyurethane-based polymers, polynorbornene-based polymer and polylactide-based polymers. 14. The system of claim 13 , wherein the hydrophilic polymer further comprises a polysaccharide. 15. The system of claim 14 , wherein the polysaccharide is a xanthan gum. 16. The system of claim 9 , wherein the delivery device includes a sharpened distal end. 17. A system, comprising: a delivery device comprising a proximal portion, distal portion and lumen extending therebetween; a first injectable composition disposed within the distal portion of the delivery device; and a second injectable composition disposed within the proximal portion of the delivery device; wherein the viscosity of the second injectable composition is at least ten times greater than the viscosity of the first injectable composition; wherein the first and second injectable compositions are separated by a barrier member; and wherein the system is configured to sequentially deliver the first and second injectable compositions. 18. The system of claim 17 , wherein the barrier member is configured to rupture above a threshold level of force. 19. The system of claim 17 , wherein the second injectable composition comprises a hydrophilic polymer selected from the group consisting of acrylate-based polymers, polyurethane-based polymers, polynorbornene-based polymer and polylactide-based polymers. 20. The system of claim 17 , wherein the delivery device is configured to be delivered through a working channel of an endoscope.

Assignees

Inventors

Classifications

  • Endoscopic cutting instruments, e.g. arthroscopes, resectoscopes (A61B10/0233, A61B17/29, A61B17/3207 take precedence) · CPC title

  • for minimally invasive surgery (A61B17/0218, A61B17/0469, A61B17/12013, A61B17/1285, A61B17/29, A61B17/320016 take precedence) · CPC title

  • Endoscopic needles, e.g. for infusion (biopsy needles A61B10/0233; catheters with injection needles A61M25/0067) · CPC title

  • Polysaccharides · CPC title

  • Materials at least partially resorbable by the body · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11793539B2 cover?
The present disclosure relates to the field of medical devices generally and specifically, to endoscopic systems and methods for resection of malignant and pre-malignant lesions within the gastrointestinal (GI) tract. In particular, the present disclosure relates to systems and methods for delivering injectable compositions between tissue layers (e.g., between the muscularis and submucosa layer…
Who is the assignee on this patent?
Boston Scient Scimed Inc
What technology area does this patent fall under?
Primary CPC classification A61B17/320016. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Oct 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).